Hana Pharm Co., Ltd. (293480.KS)
KRW 10850.0
(-0.73%)
KRW 10850.0
(-0.73%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 27.03 Billion KRW | -16.17% |
| 2022 | 31.17 Billion KRW | -13.44% |
| 2021 | 36.01 Billion KRW | 13.69% |
| 2020 | 31.67 Billion KRW | -5.64% |
| 2019 | 33.56 Billion KRW | 0.01% |
| 2018 | 33.56 Billion KRW | 5.12% |
| 2017 | 31.92 Billion KRW | 34.89% |
| 2016 | 23.67 Billion KRW | 53.3% |
| 2015 | 15.44 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 7.63 Billion KRW | 30.13% |
| 2024 Q2 | -116.96 Billion KRW | -40.12% |
| 2023 Q3 | 5.51 Billion KRW | -36.12% |
| 2023 Q4 | 5.86 Billion KRW | 6.23% |
| 2023 Q1 | 7 Billion KRW | -13.36% |
| 2023 Q2 | 8.64 Billion KRW | 23.39% |
| 2023 FY | 26.13 Billion KRW | -16.17% |
| 2022 FY | 31.17 Billion KRW | -13.44% |
| 2022 Q4 | 8.08 Billion KRW | 5.17% |
| 2022 Q3 | 7.68 Billion KRW | 4.51% |
| 2022 Q2 | 7.35 Billion KRW | -8.66% |
| 2022 Q1 | 8.05 Billion KRW | -29.82% |
| 2021 FY | 36.01 Billion KRW | 13.69% |
| 2021 Q2 | 10.63 Billion KRW | 87.08% |
| 2021 Q1 | 5.68 Billion KRW | -35.48% |
| 2021 Q4 | 11.47 Billion KRW | 39.52% |
| 2021 Q3 | 8.22 Billion KRW | -22.69% |
| 2020 Q3 | 9.49 Billion KRW | 48.68% |
| 2020 Q2 | 6.38 Billion KRW | -8.59% |
| 2020 FY | 31.67 Billion KRW | -5.64% |
| 2020 Q1 | 6.98 Billion KRW | -22.7% |
| 2020 Q4 | 8.81 Billion KRW | -7.2% |
| 2019 Q1 | 7.82 Billion KRW | -11.44% |
| 2019 FY | 33.56 Billion KRW | 0.01% |
| 2019 Q4 | 9.03 Billion KRW | -1.28% |
| 2019 Q3 | 9.15 Billion KRW | 21.28% |
| 2019 Q2 | 7.54 Billion KRW | -3.57% |
| 2018 Q3 | 8.96 Billion KRW | 6.28% |
| 2018 Q1 | 7.32 Billion KRW | 0.0% |
| 2018 FY | 33.56 Billion KRW | 5.12% |
| 2018 Q4 | 8.83 Billion KRW | -1.37% |
| 2018 Q2 | 8.43 Billion KRW | 15.03% |
| 2017 FY | 31.92 Billion KRW | 34.89% |
| 2017 Q3 | 9.43 Billion KRW | 0.0% |
| 2016 FY | 23.67 Billion KRW | 53.3% |
| 2015 FY | 15.44 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -7315.28% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 64.84% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 133.975% |
| HANDOK Inc. | 12.57 Billion KRW | -114.896% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 1458.95% |
| Yuhan Corporation | 74.56 Billion KRW | 63.747% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -141.817% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 249.821% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 87.98% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -784.52% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -88.367% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -4432.415% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -2704.775% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -7315.28% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 448.521% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -570.152% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 138.644% |
| JW Holdings Corporation | 143.66 Billion KRW | 81.184% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 150.604% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 89.038% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 73.05% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 157.038% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -290.237% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -317.73% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -209.59% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -7315.28% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 44.571% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 79.738% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 73.05% |
| Yuhan Corporation | 74.56 Billion KRW | 63.747% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -29.212% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -767.117% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 37.129% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 73.05% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -31.961% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 50.807% |
| CKD Bio Corp. | -20.15 Billion KRW | 234.134% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 16.137% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -6.835% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 16.891% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 157.038% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 18.449% |
| Boryung Corporation | 68.26 Billion KRW | 60.403% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 172.09% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -88.367% |
| JW Lifescience Corporation | 32.09 Billion KRW | 15.768% |